Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott David Solomon, M.D.

Co-Author

This page shows the publications co-authored by Scott Solomon and Eugene Braunwald.
Connection Strength

2.138
  1. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022 01 04; 145(1):87-89.
    View in: PubMed
    Score: 0.243
  2. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
    View in: PubMed
    Score: 0.240
  3. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021 06; 23(6):1040-1048.
    View in: PubMed
    Score: 0.233
  4. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2020 11 01; 5(11):1236-1244.
    View in: PubMed
    Score: 0.226
  5. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012 Jan 17; 125(2):233-40.
    View in: PubMed
    Score: 0.122
  6. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol. 2010 Oct 01; 106(7):911-6.
    View in: PubMed
    Score: 0.111
  7. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation. 2007 Dec 04; 116(23):2687-93.
    View in: PubMed
    Score: 0.092
  8. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006 Jul 04; 114(1):26-31.
    View in: PubMed
    Score: 0.083
  9. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1725-7.
    View in: PubMed
    Score: 0.082
  10. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004 Dec 14; 110(24):3667-73.
    View in: PubMed
    Score: 0.075
  11. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002 Sep 03; 106(10):1251-5.
    View in: PubMed
    Score: 0.064
  12. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 11 11; 385(20):1845-1855.
    View in: PubMed
    Score: 0.061
  13. Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019 12; 12(12):e006231.
    View in: PubMed
    Score: 0.053
  14. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Eur J Heart Fail. 2019 12; 21(12):1571-1579.
    View in: PubMed
    Score: 0.053
  15. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. Eur J Heart Fail. 2019 04; 21(4):462-470.
    View in: PubMed
    Score: 0.050
  16. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
    View in: PubMed
    Score: 0.044
  17. Sharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016 Aug 04; 375(5):407-9.
    View in: PubMed
    Score: 0.042
  18. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 06; 29(6):537-44.
    View in: PubMed
    Score: 0.041
  19. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10; 63(22):2421-8.
    View in: PubMed
    Score: 0.036
  20. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014 Jun 07; 35(22):1457-65.
    View in: PubMed
    Score: 0.035
  21. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013 Mar 26; 61(12):1240-9.
    View in: PubMed
    Score: 0.033
  22. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem. 2011 Sep; 57(9):1311-7.
    View in: PubMed
    Score: 0.030
  23. Opposing effects of ß blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011 Jun 15; 107(12):1705-9.
    View in: PubMed
    Score: 0.029
  24. Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail. 2009 May; 2(3):209-16.
    View in: PubMed
    Score: 0.025
  25. Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J. 2005 Oct; 150(4):743-9.
    View in: PubMed
    Score: 0.020
  26. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002 May 01; 39(9):1450-5.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.